[4-(4-氨基-6,7-二甲氧基喹唑啉-2-基)哌嗪-1-基](4-叠氮-3-碘苯基)甲酮 | 90990-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: [4-(4-氨基-6,7-二甲氧基喹唑啉-2-基)哌嗪-1-基](4-叠氮-3-碘苯基)甲酮
• 英文名称: iodoazidoaryl prazosin
• 英文别名: [125I]-Azidoprazosin；Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(4-azido-3-iodobenzoyl)-；[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(4-azido-3-iodophenyl)methanone
• CAS: 90990-97-9
• 化学式: C₂₁H₂₁IN₈O₃
• 分子量: 560.354
• InChiKey: HCZCARLOZFORBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-[4-(4-amino-3-iodobenzoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline 在 溶剂黄146 、 sodium nitrite 、 sodium azide 作用下， 反应 0.16h， 以65%的产率得到[4-(4-氨基-6,7-二甲氧基喹唑啉-2-基)哌嗪-1-基](4-叠氮-3-碘苯基)甲酮
  参考文献：
  名称：

  A Modified Synthesis of Iodoazidoaryl Prazosin

  摘要：

  The antihypertension agent iodoazidoaryl prazosin (IAAP) has been made using a convergent route involving addition of an acylated piperazine 7 to 2-chloroquinazoline 5. IAAP has been shown to function as a multidrug resistance (MDR) reversal agent and bind to P-glycoprotein, a transmembrane transport protein. A study is also reported involving palladium-catalyzed substitution with amine heterocycles. With N,N-bis(2,6-diisopropyl)dihydroimidazolium chloride (10) as the ligand (2 mol %) for palladium(II) acetate (2 mol %) in THF at room temperature, morpholine added to 5 in 81% yield.

  DOI：

  10.1021/jo026217o

文献信息

• USE OF PHOSPHODIESTERASE INHIBITORS FOR TREATING MULTIDRUG RESISTANCE
  申请人：CHEN Zhe-Sheng

  公开号：US20120252816A1

  公开（公告）日：2012-10-04

  The present invention relates to methods of treating multidrug resistance in cancerous cells with phosphodiesterase (PDE) inhibitors, e.g., PDE5 inhibitors. More specifically, the invention relates to methods of treating multidrug resistance that arises, e.g., during administration of chemotherapeutic/antineoplastic (anticancer) agents for treatment of cancer, with a PDE5 inhibitor (e.g., sildenafil, vardenafil, and tadalafil). The invention also relates to methods of treating cancer, e.g., multidrug resistant cancer, using a PDE5 inhibitor in combination with an antineoplastic therapeutic agent. Further, the invention relates to pharmaceutical compositions for treating multidrug resistant cancers comprising a PDE5 inhibitor, or a combination of a PDE5 inhibitor and an antineoplastic agent.
• US8673914B2
  申请人：——

  公开号：US8673914B2

  公开（公告）日：2014-03-18
• A Modified Synthesis of Iodoazidoaryl Prazosin
  作者：Merritt B. Andrus、Sashikumar N. Mettath、Chun Song

  DOI：10.1021/jo026217o

  日期：2002.11.1

  The antihypertension agent iodoazidoaryl prazosin (IAAP) has been made using a convergent route involving addition of an acylated piperazine 7 to 2-chloroquinazoline 5. IAAP has been shown to function as a multidrug resistance (MDR) reversal agent and bind to P-glycoprotein, a transmembrane transport protein. A study is also reported involving palladium-catalyzed substitution with amine heterocycles. With N,N-bis(2,6-diisopropyl)dihydroimidazolium chloride (10) as the ligand (2 mol %) for palladium(II) acetate (2 mol %) in THF at room temperature, morpholine added to 5 in 81% yield.